219 related articles for article (PubMed ID: 10945827)
1. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.
Bond A; Jones NM; Hicks CA; Whiffin GM; Ward MA; O'Neill MF; Kingston AE; Monn JA; Ornstein PL; Schoepp DD; Lodge D; O'Neill MJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):800-9. PubMed ID: 10945827
[TBL] [Abstract][Full Text] [Related]
2. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.
Bond A; Ragumoorthy N; Monn JA; Hicks CA; Ward MA; Lodge D; O'Neill MJ
Neurosci Lett; 1999 Oct; 273(3):191-4. PubMed ID: 10515191
[TBL] [Abstract][Full Text] [Related]
3. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.
Di Liberto V; Bonomo A; Frinchi M; Belluardo N; Mudò G
Neuroscience; 2010 Feb; 165(3):863-73. PubMed ID: 19909793
[TBL] [Abstract][Full Text] [Related]
4. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.
Cai Z; Xiao F; Fratkin JD; Rhodes PG
Neuroreport; 1999 Dec; 10(18):3927-31. PubMed ID: 10716235
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia.
Bond A; O'Neill MJ; Hicks CA; Monn JA; Lodge D
Neuroreport; 1998 Apr; 9(6):1191-3. PubMed ID: 9601692
[TBL] [Abstract][Full Text] [Related]
6. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
Cartmell J; Monn JA; Schoepp DD
J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-beta neurotoxicity and clearance are both regulated by glial group II metabotropic glutamate receptors.
Durand D; Carniglia L; Turati J; Ramírez D; Saba J; Caruso C; Lasaga M
Neuropharmacology; 2017 Sep; 123():274-286. PubMed ID: 28495373
[TBL] [Abstract][Full Text] [Related]
8. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.
Battaglia G; Riozzi B; Bucci D; Di Menna L; Molinaro G; Pallottino S; Nicoletti F; Bruno V
Neurobiol Dis; 2015 Feb; 74():126-36. PubMed ID: 25434487
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys.
Adewale AS; Platt DM; Spealman RD
J Pharmacol Exp Ther; 2006 Aug; 318(2):922-31. PubMed ID: 16675638
[TBL] [Abstract][Full Text] [Related]
11. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
12. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.
Caraci F; Molinaro G; Battaglia G; Giuffrida ML; Riozzi B; Traficante A; Bruno V; Cannella M; Merlo S; Wang X; Heinz BA; Nisenbaum ES; Britton TC; Drago F; Sortino MA; Copani A; Nicoletti F
Mol Pharmacol; 2011 Mar; 79(3):618-26. PubMed ID: 21159998
[TBL] [Abstract][Full Text] [Related]
13. Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.
Stover JF; Sakowitz OW; Beyer TF; Dohse NK; Kroppenstedt SN; Thomale UW; Schaser KD; Unterberg AW
J Neurotrauma; 2003 Apr; 20(4):315-26. PubMed ID: 12866811
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia.
Yoshioka H; Sugita M; Kinouchi H
Neurosci Lett; 2009 Sep; 461(3):266-70. PubMed ID: 19549561
[TBL] [Abstract][Full Text] [Related]
15. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268.
Johnson MP; Chamberlain M
Neuropharmacology; 2002 Oct; 43(5):799-808. PubMed ID: 12384165
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex.
Okamura N; Hashimoto K; Shimizu E; Koike K; Ohgake S; Koizumi H; Kumakiri C; Komatsu N; Iyo M
Brain Res; 2003 Nov; 992(1):114-9. PubMed ID: 14604779
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine.
Cartmell J; Monn JA; Schoepp DD
Psychopharmacology (Berl); 2000 Mar; 148(4):423-9. PubMed ID: 10928316
[TBL] [Abstract][Full Text] [Related]
18. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.
Cartmell J; Monn JA; Schoepp DD
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):39-46. PubMed ID: 10651145
[TBL] [Abstract][Full Text] [Related]
19. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.
Cartmell J; Monn JA; Schoepp DD
Eur J Pharmacol; 2000 Jul; 400(2-3):221-4. PubMed ID: 10988337
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
